A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2001
11/08/2001	WO2001083031A2 Topical composition for the treatment of psoriasis and related skin disorders
11/08/2001	WO2001083020A1 Antineoplastic platinum therapeutic method and composition
11/08/2001	WO2001082981A1 A medicinal aerosol formulation
11/08/2001	WO2001082975A2 Membrane-permeant peptide complexes for medical imaging
11/08/2001	WO2001082971A2 Cyclodextrin containing glycopeptide antibiotic compositions
11/08/2001	WO2001082970A1 Mixtures of triblock polyesterpolyethylene glycol copolymers
11/08/2001	WO2001082968A1 Cell proliferation inhibitors
11/08/2001	WO2001082961A2 Methods for treating bone tumors
11/08/2001	WO2001082960A1 Inhibition of polyclonal b cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking cd1-mediated interactions
11/08/2001	WO2001082956A1 Pharmaceutical composition
11/08/2001	WO2001082955A1 Depletion method of blood plasma ascorbate
11/08/2001	WO2001082954A2 Ceruloplasmin and uses thereof in neurodegenerative related conditions
11/08/2001	WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001	WO2001082951A1 Treatment of damaged connective tissue
11/08/2001	WO2001082950A1 Pernasally absorbable insulin preparations
11/08/2001	WO2001082949A2 Method of reducing side effects of chemotherapy in cancer patients
11/08/2001	WO2001082948A2 Uses of tgap7 for the modulation of leucocyte activation
11/08/2001	WO2001082947A1 Method and apparatus for vascular neuromuscular blockade
11/08/2001	WO2001082946A2 Neuroprotective compositions
11/08/2001	WO2001082945A2 The use of bacterial phage associated lysing enzymes for treating various illnesses
11/08/2001	WO2001082944A1 Methods and compositions for impairing multiplication of hiv-1
11/08/2001	WO2001082943A2 Subcutaneous administration of coagulation factor vii
11/08/2001	WO2001082937A1 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use
11/08/2001	WO2001082932A2 Methods and compositions for enhancing cellular function through protection of tissue components
11/08/2001	WO2001082914A2 Topical anesthetic/opioid formulations and uses thereof
11/08/2001	WO2001082910A2 Combination of progesterone and mifepristone for cancer therapy
11/08/2001	WO2001082906A1 Powders for use in a dry powder inhaler
11/08/2001	WO2001082902A1 Method and composition for rapid delivery of bioactive compounds to the systemic circulation via the nasal membrane
11/08/2001	WO2001082900A1 Non-invasive gene targeting to the brain
11/08/2001	WO2001082897A2 Liposome drug delivery
11/08/2001	WO2001082874A2 A medicinal aerosol formulation
11/08/2001	WO2001082872A2 A medicinal aerosol formulation
11/08/2001	WO2001082870A2 A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
11/08/2001	WO2001082863A2 Polyacid/polyalkylene oxide foams and gels and methods for their delivery
11/08/2001	WO2001082862A2 P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof
11/08/2001	WO2001082699A1 A gene therapy system and method using alpha-msh and its derivatives
11/08/2001	WO2001058493A8 Conjugates of follicle stimulating hormones
11/08/2001	WO2001042435A3 Novel human kinase proteins and polynucleotides encoding the same
11/08/2001	WO2001040460A8 Screening method for compounds capable of modularing egr-1-regulated expression
11/08/2001	WO2001040180A3 N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents
11/08/2001	WO2001037780A8 Urotensin-ii analogs
11/08/2001	WO2001036630A3 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
11/08/2001	WO2001036489A3 Erythropoietin forms with improved properties
11/08/2001	WO2001034183A3 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
11/08/2001	WO2001034180A3 Interferon gamma for the treatment of asthma
11/08/2001	WO2001032697A3 Virulence genes and proteins from brucella melitensis, and their use
11/08/2001	WO2001032614A3 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof
11/08/2001	WO2001032128A3 Human chemokine beta-13
11/08/2001	WO2001030810A3 Relaxase and other vir proteins as targets for treatment of helicobacter pylori infection and as dna transfer system to mammalian cells
11/08/2001	WO2001030383A3 Medicament in order to induce tolerance
11/08/2001	WO2001029068A3 A eag gene encoding for a potassium channel
11/08/2001	WO2001028582A3 Therapeutic applications of flint polypeptides
11/08/2001	WO2001028574A3 Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain
11/08/2001	WO2001023553A3 Metastasis-associated antigen c4.4a
11/08/2001	WO2001018037A3 A p53-induced protein with a death domain that can promote apoptosis
11/08/2001	WO2001018035A3 Muc-1 derived peptides
11/08/2001	WO2001008707A3 Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
11/08/2001	WO2001007468A3 Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
11/08/2001	WO2001006843A8 Promotion of proliferation of adult corneal endothelial cells
11/08/2001	WO2001005963A3 ANTISENSE OLIGONUCLEOTIDES FOR METABOTROPIC GLUTAMATE RECEPTOR TYPE 1 (mGluR1)
11/08/2001	WO2000074666A3 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
11/08/2001	WO2000069897A3 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
11/08/2001	WO2000060359A9 Interactions of ku polypeptides
11/08/2001	WO2000001841A3 Hyaluronic acid mimics and methods related thereto
11/08/2001	US20010039667 Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease
11/08/2001	US20010039438 Method for treating neovascularization
11/08/2001	US20010039414 Sustained release delivery systems for solutes
11/08/2001	US20010039335 Genetic engineering
11/08/2001	US20010039293 4((4-chloro-3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro -naphathalene-2-carbonyl)-amino)-2,6-difluoro-benzoic acid or its esters or salts used as agonists of alpha-retinoid receptors (=raralpha)
11/08/2001	US20010039285 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
11/08/2001	US20010039274 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease
11/08/2001	US20010039261 Administration of polypeptide growth factors following central nervous system ischemia or trauma
11/08/2001	US20010039260 Pulmonary insulin crystals
11/08/2001	US20010039259 Administering hematopoietic cell stimulating factor, the dosage being sufficient to cause increase in population of hematopoietic cells and in differentiated blood cells, administering chemotherapeutic agents or cytotoxic irradiation
11/08/2001	US20010039258 Exposing biologically active agent to complexing perturbant to reversibly transform biologically active agent to intermediate state and to form a subcutaneously deliverable supramolecular complex, subcutaneously administering complex
11/08/2001	US20010039257 Augmenting actions of cAMP in an effector system while reducing cAMP action in a nociceptive system comprising application of one or more forms of nitrogen oxide or carbon monoxide to a site wherein cAMP exists
11/08/2001	US20010039256 Administering to subject a polypeptide derived from soluble receptor for advanced glycation end product
11/08/2001	US20010039051 Utlizing the Varicella-Zoster virus protein's ability to enter and exit eukaryotic cells for drug or secreting agent delivery
11/08/2001	US20010039038 Novel glucosaminidase
11/08/2001	US20010039036 Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily
11/08/2001	US20010039027 Cyclitol containing carbohydrates from human tissue which regulate lipogenic activity
11/08/2001	US20010039017 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
11/08/2001	US20010039016 Measurement, calibration gene expression
11/08/2001	US20010038859 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
11/08/2001	US20010038845 Parenterally administering large liposomes comprised of phospholipids free of sterol which pick-up cholesterol druing the treatment period; liposomes too large to penetrate fenestrations of endothelial lining hepatic sinusoids
11/08/2001	US20010038842 Treating a disease characterized by expression of vascular endothelial growth factor-D (VEGF-D) by a tumor by screening for a VEGF-D expressing tumor, administering a VEGF-D antagonist to prevent binding of VEGF-D to its receptor
11/08/2001	US20010038839 A polypeptide which is capable of binding to one of low affinity immunoglobulin-E receptor (FCEL) or high affinity receptor (FCEH) but which is substantially incapable of binding to other of FCEL OR FCEH
11/08/2001	US20010038834 A therapeutic agent, comprising a bone marrow cell which has been transfected with DNA operably connected to a promoter, which DNA encodes the expression of antitumer agent when introduced into a mammal, homes to bone marrow of the mammal
11/08/2001	US20010038833 Melanoma therapy
11/08/2001	US20010038832 Administering an effective amount interferon-gamma and a sensitizing agent selected from atlest nitrogen oxide, nitrogen oxide synthase type II (iNOS) nitrogen oxide donar and nitrogen oxide mimics for treating cancer
11/08/2001	US20010038824 Aerothricins antifungal cyclic peptides
11/08/2001	US20010037805 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
11/08/2001	DE10018980A1 Prophylaxe und Therapie von Diabetes mellitus I mit Hilfe proteolytischer Enzyme Prophylaxis and therapy of diabetes mellitus I with the aid of proteolytic enzymes
11/08/2001	DE10018098A1 Treatment of cancer by apoptosis induction comprises administration of amino acid and saturated fatty acid derivatives
11/08/2001	CA2750984A1 Porphyromonas gingivalis recombinant proteins and truncations
11/08/2001	CA2726789A1 Cyclodextrin containing glycopeptide antibiotic compositions
11/08/2001	CA2443555A1 Enzymes useful for treating and methods for treating mps-vi and cells lines for producing such enzymes recombinantly
11/08/2001	CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2414290A1 Anti-inflammatory compounds and uses thereof

1 ... 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 ... 3163